anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the active and transitional phase, squatting position (squatting with feet shoulder-width apart by laying a clean sheet on the floor and getting support from a bed, chair or birth ball) during contractions (average 25 minutes). In order to monitor the condition of the fetus, the squatting position was used by the pregnant woman during contractions while connected to the NST.
This arm increases antibiotic stewardship education and interventions. Program 2 hospitals performed audit and feedback of pre-specified antibiotics and implemented locally controlled restrictions.
The invention discloses a polymer medicament containing polyacrylic acid. Acrylic acid is subjected to an atom transfer radical polymerization reaction to obtain polyacrylic acid. Glutamic acid octadecanyl glutamate carboxylic acid anhydride is subjected to a ring-opening polymerization reaction to obtain poly(octadecanyl glutamate). The poly(octadecanyl glutamate) is grafted to doxorubicin through a hydrazone bond. The polyacrylic acid is bonded to the poly(octadecanyl glutamate) in a manner of click chemistry to obtain a block copolymer. The block copolymer is respectively dissolved in tetrahydrofuran to obtain a solution. The solution is transferred to a dialysis bag for carrying out a dialysis process through pure water to obtain a dialysate which is filtered through a filter membrane. A freeze drying process is carried out to the filtered solution to obtain a medicament carrier micelle. The drug carrier micelle has a core-shell double-layer structure with an external layer being hydrophilic polyacrylic acid and an internal layer being medicament molecule wrapping layer. The drug carrier micelle has advantages of belonging to nano particles and enabling a targeting transmission of a drug to cancer cells and a pH-sensitive releasing process in the cancer cells to be achieved. The drug carrier micelle is large in drug carrying capacity and good in stability. A targeting function of the drug carrier micelle can effectively reduce toxic and side effects of drugs on normal tissues and organs.
The present invention relates to a Planococcus sp. strain having astaxanthin secreting ability, and uses thereof. In the present invention, a novel microorganism secreting astaxanthin has been identified from a  Planococcus  sp. strain secreting a carotenoid compound. Accordingly, the  Planococcus  sp. strain of the present invention is a novel microorganism that secretes astaxanthin, and has potential to be efficiently utilized as feed, a food additive, a cosmetic, and the like.
BACKGROUND: 2'-Fucosyllactose (2'-FL) is an oligosaccharide contained in human milk and possesses prebiotic and anti-inflammatory effects, which may alleviate skeletal muscle atrophy under caloric restriction. This study evaluated the impacts of 12 weeks of 2'-FL supplementation in conjunction with exercise (10,000 steps/day, 5 days/week) and energy-reduced (-300 kcals/day) dietary interventions on changes in body composition and health-related biomarkers.
METHODS: A total of 41 overweight and sedentary female and male participants (38.0 ± 13 years, 90.1 ± 15 kg, 31.6 ± 6.6 kg/m2, 36.9 ± 7% fat) took part in a randomized, double-blind, and placebo-controlled study. The participants underwent baseline assessments and were then assigned to ingest 3 g/day of a placebo (PLA) or Momstamin 2'-F while initiating the exercise and weight-loss program. Follow-up tests were performed after 6 and 12 weeks. Data were analyzed using general linear model statistics with repeated measures and mean changes from baseline values with 95% confidence intervals (CIs).
RESULTS: No group × time × sex interaction effects were observed, so group × time effects are reported. Participants in both groups saw comparable reductions in weight. However, those with 2'-FL demonstrated a significantly greater reduction in the percentage of body fat and less loss of the fat-free mass. Additionally, there was evidence that 2'-FL supplementation promoted more favorable changes in resting fat oxidation, peak aerobic capacity, IL-4, and platelet aggregation, with some minimal effects on the fermentation of short-chain fatty acids and monosaccharides in fecal samples. Moreover, participants' perceptions regarding some aspects of the functional capacity and ratings of the quality of life were improved, and the supplementation protocol was well tolerated, although a small, but significant, decrease in BMC was observed.
CONCLUSIONS: The results support contentions that dietary supplementation of 2'-FL (3 g/d) can promote fat loss and improve exercise- and diet-related markers of health and fitness in overweight sedentary individuals initiating an exercise and weight-loss program. Further research is needed to explore the potential health benefits of 2'-FL supplementation in both healthy and elderly individuals (Registered clinical trial #NCT06547801).
Octanorm (cutaquig®) is a 16.5% human normal immunoglobulin solution developed by Octapharma for subcutaneous administration (SCIG). It is supplied as a liquid formulation ready to use. One important therapeutic use of immunoglobulins is to provide antibodies to prevent viral and bacterial diseases (replacement therapy). Children and adults with a Primary Immunodeficiency Disease (PID) have an increased risk of recurrent bacterial and viral infections. These diseases can be severe and can lead to substantial morbidity. Responses to antibacterial therapy are often poor. At present, most primary immune deficiencies are not curable, but SCIGs have been shown to decrease the total number of severe infections and the duration of hospitalization. This study evaluated the efficacy, safety and tolerability of octanorm in adult PID patients in an open-label, multi center, phase 3 study with an 8-week wash-in/wash-out period followed by a 6-month efficacy period
In period III (double-blind withdrawal ): At visit 4, part of the patients from Aliskiren arm received placebo to Aliskiren for 1 day. The study ended at visit 5 (48 hours later than visit 4).
The artificial pancreas device will employ its enhanced Model Predictive Control (MPC) algorithm with a target glucose level of 110 mg/dL with a trust index for MPC-predicted glucose values, weighing future glucose predictions and only acting on predictions with higher weight in the trust index. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
Drug intervention of fesoterodine 4 mg once a day in the morning after the two-week washout period. They will have the option to escalate to 8 mg (2 tablets of 4 mg each) after 4 weeks on fesoterodine. Patients will have the option to go back to one tablet (i.e., 4 mg) at any time in the study.
When nasal steroids are used at higher than recommended dosages or in susceptible individuals at recommended dosages, systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear. If such changes occur, the dosage of azelastine hydrochloride and fluticasone propionate nasal spray should be discontinued slowly, consistent with accepted procedures for discontinuing oral corticosteroid therapy. The concomitant use of nasal corticosteroids with other inhaled corticosteroids could increase the risk of signs or symptoms of hypercorticism and/or suppression of the HPA axis.

The replacement of a systemic corticosteroid with a topical corticosteroid can be accompanied by signs of adrenal insufficiency, and in addition some patients may experience symptoms of withdrawal, e.g., joint and/or muscular pain, lassitude, and depression. Patients previously treated for prolonged periods with systemic corticosteroids and transferred to topical corticosteroids should be carefully monitored for acute adrenal insufficiency in response to stress. In those patients who have asthma or other clinical conditions requiring long-term systemic corticosteroid treatment, too rapid a decrease in systemic corticosteroids may cause a severe exacerbation of their symptoms.
Participants randomized to the mobile app arm, received an email asking them to download the app and activate their account. Users who did not activate their account after 48 hours received a reminder email. Participants who activated their accounts, could spontaneously report an adverse event through the app, and were also notified of the day 8 survey through the app.
FIELD: medicinal biotechnology. SUBSTANCE: method involves culturing microorganism-producer followed by inactivation, separation and mechanical disruption of microbial cells and isolation of fimbrias by precipitation with ammonium sulfate. Before disruption microbial cells were washed off with sodium chloride saturated solution and the isolated fimbrias were subjected for dialysis against phosphate buffer followed by ultrasonic or chemical disruption, gel-filtration and concentration by treatment with polyethylene glycol. Obtained bacterial fimbrial adhesine can be used as diagnostic and prophylaxis preparation. EFFECT: improved method of preparing. 3 tbl
The maximum recommended dose is 22,000 mm2 of RETHYMIC/m2 recipient body surface area (BSA). Standard clinical care is recommended for patients receiving a dose > 22,000 mm2 of RETHYMIC/m2 recipient BSA. The product, as provided, has been adjusted at the manufacturing facility to not exceed the maximum dose based on the patient body surface area.

During clinical development one patient received a dose higher (23,755 mm2/m2) than the maximum recommended dose. This patient developed enteritis. A biopsy showed T cell, B cell, and neutrophil infiltration of the gut which resolved after treatment with immunosuppression, 5 months after treatment with RETHYMIC. The enteritis may have been related to the high dose of RETHYMIC.
Dissemination of available materials explaining the Collaborative Chronic Care Model and implementation tools. Sites randomized to delay initiation of facilitation will have these materials plus technical assistance for 4 or 8 months prior to full implementation facilitation.
1,174,672. Ointment base. V. K. LARSSON. 2 Oct., 1967 [30 Sept., 1966], No. 44683/ 67. Heading A5B. Ointment bases for dermatological (including medical and cosmetic) purposes, comprising an aqueous dispersion of crystals of at least one α-mono-glyceride of a fatty acid (preferably with a chain containing 12-18 carbon atoms) dispersed in an aqueous phase consisting essentially of water; wherein the water comprises 50-90% by weight of the dispersion and the molecular orientation of the α-monoglyceride in the crystal is such that the crystal surface is formed substantially by the polar glycerol end groups giving hydrophilic properties to the crystals, are prepared by mixing together water and the glyceride and bringing this mixture to a temperature above the transition temperature (e.g. 5 to 15C. above, the transition temperature being defined as the lowest temperature at which a particle of the glyceride, in contact with excess water, absorbs water and is transformed into cylindrical or spherical particles of strong birefring- ence), keeping the mixture above the transition temperature while stirring until the glyceride has been transformed into microscopic liquidcrystalline particles and equilibrium is reached, and cooling the mixture slowly (e.g. at a rate of 0.5 to 5C per minute) while stirring to ambient temperature. The α-monoglyceride may be selected from α-monolaurin, α-monomyristin, α-monopalmitin and α-monostearin.
Subjects assigned to this group will be asked to perform Motor Imagery and Action Observation Training during immobilisation period after surgery. The training will be performed once a day, for three weeks. The duration of the training will last about 15 minutes.
The effectiveness study will be conducted as a randomized controlled trial with an intervention group and a waiting-list control group. Data will be collected at baseline (T1, pre intervention) and after about 2 weeks of intervention (T2, post intervention). A follow-up evaluation (T3) will be conducted after about 3 months to examine if the effects were stable over time.
This article explores the ethical implications of mandatory parental consent requirements for adolescents seeking sexual and reproductive health services (SRHS). Using a Reproductive Justice framework, which identifies systemic barriers to accessing healthcare services, we examine ageism as a potential factor restricting adolescents' access to SRHS. While the Reproductive Justice framework has addressed systemic issues like racism and ableism in healthcare, ageism involving adolescents has been less explored. The article challenges the pertinence of mandatory parental consent requirements-as a potential barrier-for adolescents' access to SRHS. We argue that in the specific context of SRHS (contraceptives, abortion, testing and treatment of sexually transmitted infections), adolescents' autonomy (self-determination) should be respected if they request to access those services independently. From a global health perspective, adolescents have a low prevalence and uneven access to SRHS. To address the issue, we propose the integration of adolescence into the Reproductive Justice movement to empower them through education on how to access the SRHS they need.
The susceptibility modules and characteristic genes of patients with osteoarthritis (OA) were determined by weighted gene co-expression network analysis (WGCNA), and the role of immune cells in OA related microenvironment was analyzed. GSE98918 and GSE117999 data sets are from GEO database. R language was used to conduct difference analysis for the new data set after merging. The formation of gene co-expression network, screening of susceptibility modules and screening of core genes are all through WGCNA. GO and KEGG enrichment analyses were used for Hub genes. The characteristic genes of the disease were obtained by Lasso regression screening. SSGSEA was used to estimate immune cell abundance in sample and a series of correlation analyses were performed. WGCNA was used to form 6 gene co-expression modules. The yellow-green module is identified as the susceptible module of OA. 202 genes were identified as core genes. Finally, RHOT2, FNBP4 and NARF were identified as the characteristic genes of OA. The results showed that the characteristic genes of OA were positively correlated with plasmacytoid dendritic cells, NKT cells and immature dendritic cells, but negatively correlated with active B cells. MDSC were the most abundant immune cells in cartilage. This study identified the Hippo signaling pathway, mTOR signaling pathway, and three characteristic genes (RHOT2, FNBP4, NARF) as being associated with osteoarthritis (OA). These three genes are downregulated in the cartilage of OA patients and may serve as biomarkers for early diagnosis and targeted therapy. Proper regulation of immune cells may aid in the treatment of OA. Future research should focus on developing tools to detect these genes and exploring their therapeutic applications.
Disclosed are therapeutic hydrogels for atopic dermatitis and a method for preparing the same. The hydrogels comprises a biocompatible polymer, a polyalcohol, and a medicinal plant extract. The hydrogels can carry medicinally effective ingredients for a sustained period of time and absorb wound exudates properly. The hydrogels have suitable gel strength and, when applied to a wound, can prevent bacterial infection of the wound. Moreover, the methods employing radiation allow the polymer chains to be crosslinked to each other, and also bring about a sterilization effect in the final hydrogel. There are no problems of toxic residues in the hydrogels. They are easy to attach to the skin and concomitantly provide a cool feeling. Supported by the laminate of hydrophilic nonwoven fabric sheet and polyethylene film, the hydrogel retain water for a prolonged period of time and thus are useful in the treatment of contact dermatitis and atopic dermatitis.
The present invention relates to a valaciclovir hydrochloride dispersible tablet and a preparation method thereof. The dispersible tablet contains 22.1 to 56.2 wt% of valacyclovir hydrochloride, 28.3 to 67.3 wt% of filler starch, cellulose microcrystalline and/or calcium hydrogenphosphate dihydrate, 4.3 to 20.3 wt% of sodium carboxyl methylstarch, hyprolose, crosslinked polyvinylpyrrolidone and/or crosslinked carmethose, 0.13 to 1.4 wt% of polyvinylpyrrolidone or hypromellose, 0.9 to 8.1 wt% of saccharin sodium dihydrate, aspartame or stevioside, 0 to 0.7 wt% of menthol, 0.25 to 1 wt% of magnesium stearate, and 0.25 to 2.3 wt% of talc powder or gum arabic. Because the dispersible tablet of the present invention has the unique properties of short disintegration time, good dispersed state, rapid dissolution of drugs, high biologic utilization degree, convenient administration, etc., the process technology of the dispersible tablet is the same as the process technology of the general non-coated tablet. No special equipment is needed and the production cost is lower. The dispersible tablet of the present invention can be entirely disintegrated and dispersed in water of the indoor temperature within 3 minutes, and the granules can pass through a No. 2 sieve.
PURPOSE:A hair rinse composition having improved easy hairdressing and set retaining ability, containing a monoalkyl quaternary ammonium salt, and a phosphoric ester of an addition polymer of a compound containing active hydrogens with a polyoxyalkylene oxide. CONSTITUTION:A hair rinse composition containing (A) 0.1-20wt% monoalkyl quaternary ammonium salt, and (B) 0.1-30wt% phosphoric ester of addition polymer of a compound containing 2-6 active hydrogens with a polyoxyalkylene (0-50wt% oxyethylene content). The hair rinse has both rinse providing effect such as flexibility and hairdressing providing effect. A compound shown by the formula (R<1> is 8-22C alkyl, or hydroxyalkyl; R<2>-R<4> are alkyl, benzyl, etc.; X is halogen, etc.) is used advantageously as the component A, and an alcohol, polyalkylene polyamine, etc. is preferable as the compound containing active hydrogens of the component B.
The invention discloses a blood fat reducing trichosanthes seed oil compound which comprises trichosanthes seed oil and hawthorn leaf extract as effective components. The mass ratio of the snakegourd seed oil to the hawthorn leaf extract is 12.5-50: 1. The content of linoleic acid in the trichosanthes seed oil is more than or equal to 35 percent, the content of trichosanthes acid is more than or equal to 20 percent, and the content of unsaturated fatty acid is more than or equal to 80 percent. The content of total flavonoids in the hawthorn leaf extract is more than or equal to 75 percent. The invention has the beneficial effects that: compared with a model group, the trichosanthes seed oil and the compound thereof have significant differences in the reduction of TC and TG in serum, and the serum LDL-C of each dose group is not significantly higher than that of the model control group, and the serum HDL-C is not significantly lower than that of the model control group, so that the positive result of the animal experiment for assisting the reduction of TC and TG in the test sample can be judged. The compound has obvious in-vivo antioxidant activity and has certain repairing effect on the liver and aorta of a mouse.
The EndoBarrier Gastrointestinal Liner device received CE Mark for 12 months implant duration on 11 December 2009 and is a single use, minimally invasive device, used to achieve weight loss and improve Type 2 Diabetes status in subjects who are obese. The intent of the EndoBarrier Gastrointestinal Liner is to mimic portions of the standard Roux-en-Y bypass procedure. The device consists of 3 components: the implant, the delivery system, and the removal system. At study visit 4, after eight hours fasting, 80 subjects will arrive to the pre- assessment unit as part of the theatres at St. Mary's Hospital or Southampton Hospital and receive the EndoBarrier TM Gastrointestinal Liner as part of the EndoBarrier Arm Intervention.
AIMS: To describe treatment pathways for key glucose-lowering therapies in individuals with chronic kidney disease (CKD) and type 2 diabetes (T2D) using retrospective data from DISCOVER CKD (NCT04034992).
METHODS: Data were extracted from the UK Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics data (2008-2020) and the US integrated Limited Claims and Electronic Health Records Database (LCED; 2012-2019). Eligible individuals were aged ≥18 years with CKD, identified by two consecutive estimated glomerular filtration rate (eGFR) measures (15-<75 mL/min/1.73 m2 ; 90-730 days apart; index date was the second measurement) and T2D. Chronological treatment pathways for glucose-lowering therapies prescribed on or after CKD index to end of follow-up were computed. Median time and proportion of overall follow-up time on treatment were described for each therapy by database and by eGFR and urinary albumin-to-creatinine ratio (UACR) categories.
RESULTS: Of 36,951 and 4339 eligible individuals in the CPRD and LCED, respectively, median baseline eGFR was 67.8 and 64.9 mL/min/1.73 m2 ; 64.2 and 63.9% received metformin prior to index; and median (interquartile range) time on metformin during follow-up was 917 (390-1671) and 454 (192-850) days (accounting for ~75% of follow-up time in both databases). The frequency of combination treatment increased over time. There were trends towards decreased metformin prescriptions with decreasing eGFR and increasing UACR within each eGFR category.
CONCLUSIONS: Individuals with CKD and T2D had many combinations of therapies and substantial follow-up time on therapy. These results highlight opportunities for improved CKD management.
1,219,869. Stable estrogenic compositions. SOC. FARMACEUTICI ITALIA. 21 July, 1969 [24 July, 1968], No. 36514/69. Heading C2U. [Also in Division A5] A stable composition comprises an intimate mixture of an alkali metal salt of an estrogen sulphate with an aminoacid or a salt thereof. Preferred compositions comprise the sodium or potassium salt of estrone or equilin sulphate and glycine, L-lysine, L-arginine, L-ornithine or the hydrochloride, carbonate, or sulphate salts thereof. The composition may be prepared by mixing the components thereof either directly or with a solvent which is later removed.
Reconstituted DFMO powder by mouth for 14 days and celecoxib capsule by mouth daily in each cycle. Cyclophosphamide and Topotecan IV on days 8-12 in cycle 1 and days 1-5 of cycles 2-17. Patients may continue for up to 17 cycles as long as therapy is tolerated (no DLT) and disease progression does not occur (SD or better). \*Cycle 1 will include a 7 day lead-in with DFMO and celecoxib to deplete tumor polyamines.
Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.